Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

123 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Plasma concentrations of maraviroc and raltegravir after dual therapy in patients with long-term suppressed viraemia: ROCnRAL ANRS 157 study.
Lê MP, Soulié C, Assoumou L, Valantin MA, Duvivier C, Chas J, Ponscarme D, Marcelin AG, Calvez V, Katlama C, Peytavin G; ROCnRAL ANRS 157 Study Group. Lê MP, et al. Among authors: assoumou l. J Antimicrob Chemother. 2015 Aug;70(8):2418-20. doi: 10.1093/jac/dkv113. Epub 2015 Apr 26. J Antimicrob Chemother. 2015. PMID: 25917348 Clinical Trial. No abstract available.
DORAVIR: a French national survey of people with HIV-1 treated with an antiretroviral regimen including doravirine.
Soulie C, Balde A, Fofana D, Charpentier C, Bonnafous P, Sourice J, De Monte A, Avettand-Fenoel V, Le Guillou-Guillemette H, Bocket L, Raymond S, Marque Juillet S, Trabaud MA, Montes B, Maillard A, Hartard C, Alessandri-Gradt E, Brochot E, Signori-Schmuck A, Assoumou L, Marcelin AG. Soulie C, et al. Among authors: assoumou l. J Antimicrob Chemother. 2024 Jun 17:dkae194. doi: 10.1093/jac/dkae194. Online ahead of print. J Antimicrob Chemother. 2024. PMID: 38884154
Doxycycline prophylaxis and meningococcal group B vaccine to prevent bacterial sexually transmitted infections in France (ANRS 174 DOXYVAC): a multicentre, open-label, randomised trial with a 2 × 2 factorial design.
Molina JM, Bercot B, Assoumou L, Rubenstein E, Algarte-Genin M, Pialoux G, Katlama C, Surgers L, Bébéar C, Dupin N, Ouattara M, Slama L, Pavie J, Duvivier C, Loze B, Goldwirt L, Gibowski S, Ollivier M, Ghosn J, Costagliola D; ANRS 174 DOXYVAC Study Group. Molina JM, et al. Among authors: assoumou l. Lancet Infect Dis. 2024 May 23:S1473-3099(24)00236-6. doi: 10.1016/S1473-3099(24)00236-6. Online ahead of print. Lancet Infect Dis. 2024. PMID: 38797183
Efficacy and safety of three antiretroviral therapy regimens for treatment-naive African adults living with HIV-2 (FIT-2): a pilot, phase 2, non-comparative, open-label, randomised controlled trial.
Eholie SP, Ekouevi DK, Chazallon C, Charpentier C, Messou E, Diallo Z, Zoungrana J, Minga A, Ngom Gueye NF, Hawerlander D, Dembele F, Colin G, Tchounga B, Karcher S, Le Carrou J, Tchabert-Guié A, Toni TD, Ouédraogo AS, Bado G, Toure Kane C, Seydi M, Poda A, Mensah E, Diallo I, Drabo YJ, Anglaret X, Brun-Vezinet F; FIT-2 study group. Eholie SP, et al. Lancet HIV. 2024 Jun;11(6):e380-e388. doi: 10.1016/S2352-3018(24)00085-7. Epub 2024 May 10. Lancet HIV. 2024. PMID: 38740027 Free article. Clinical Trial.
Plasma concentrations of antiretroviral drugs in a successful 4-days-a-week maintenance treatment strategy in HIV-1 patients (ANRS 170-Quatuor trial).
Abe E, Landman R, Assoumou L, Amat K, Lambert-Niclot S, Bellet J, Gibowski S, Girard PM, Morand-Joubert L, de Truchis P, Alvarez JC. Abe E, et al. Among authors: assoumou l. J Antimicrob Chemother. 2024 Jun 3;79(6):1380-1384. doi: 10.1093/jac/dkae112. J Antimicrob Chemother. 2024. PMID: 38656448 Clinical Trial.
High proportion of post-migration HIV acquisition in migrant men who have sex with men receiving HIV care in the Paris region, and associations with social disadvantage and sexual behaviours: results of the ANRS-MIE GANYMEDE study, France, 2021 to 2022.
Palich R, Arias-Rodríguez A, Duracinsky M, Le Talec JY, Rousset Torrente O, Lascoux-Combe C, Lacombe K, Ghosn J, Viard JP, Pialoux G, Ohayon M, Duvivier C, Velter A, Ben Mechlia M, Beniguel L, Grabar S, Melchior M, Assoumou L, Supervie V; GANYMEDE study group; Collaborators. Palich R, et al. Among authors: assoumou l. Euro Surveill. 2024 Mar;29(11):2300445. doi: 10.2807/1560-7917.ES.2024.29.11.2300445. Euro Surveill. 2024. PMID: 38487889 Free PMC article.
Switching to dolutegravir plus rilpivirine versus maintaining current antiretroviral therapy regimen in virologically suppressed people with HIV-1 and the Lys103Asn (K103N) mutation: 48-week results from a randomised, open-label pilot clinical trial.
Moyle G, Assoumou L, de Castro N, Post FA, Curran A, Rusconi S, De Wit S, Stephan C, Raffi F, Johnson M, Masia M, Vera J, Jones B, Grove R, Fletcher C, Duffy A, Morris K, Pozniak A; NEAT ID Foundation and the WISARD study group. Moyle G, et al. Among authors: assoumou l. Lancet HIV. 2024 Mar;11(3):e156-e166. doi: 10.1016/S2352-3018(23)00292-8. Lancet HIV. 2024. PMID: 38417976 Clinical Trial.
Ex-vivo rectal tissue infection with HIV-1 to assess time to protection following oral preexposure prophylaxis with tenofovir disoproxil/emtricitabine.
Chawki S, Goldwirt L, Mouhebb ME, Gabassi A, Taouk M, Bichard I, Loze B, Amara A, Brand R, Siegel A, McGowan I, Costagliola D, Assoumou L, Molina JM, Delaugerre C; ANRS PREVENIR Study group. Chawki S, et al. Among authors: assoumou l. AIDS. 2024 Mar 15;38(4):455-464. doi: 10.1097/QAD.0000000000003789. Epub 2023 Nov 22. AIDS. 2024. PMID: 37976073 Free PMC article.
Long-term effects on subclinical cardiovascular disease of switching from boosted protease inhibitors to dolutegravir.
González-Cordón A, Assoumou L, Moyle G, Waters L, Johnson M, Domingo P, Fox J, Stellbrink HJ, Guaraldi G, Masiá M, Gompels M, De Wit S, Florence E, Esser S, Raffi F, Behrens G, Pozniak A, Gatell JM, Martínez E; NEAT 022 Study Group. González-Cordón A, et al. Among authors: assoumou l. J Antimicrob Chemother. 2023 Sep 5;78(9):2361-2365. doi: 10.1093/jac/dkad247. J Antimicrob Chemother. 2023. PMID: 37539492
123 results